Methods of treating diabetes using IL-1beta antibodies

Abstract

An IL-1β binding molecule, in particular an antibody to human IL-1β, especially a human antibody to human IL-1β is provided, wherein the CDRs of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides.

1 . A method of treating or preventing juvenile diabetes or type I diabetes comprising, administering a effective amount of antibody to human interleukin-1beta (IL-1β) or an antigen-binding fragment thereof to a patient in need thereof. 
     
     
         2 . The method according to  claim 1 , wherein the antibody is a chimeric or a CDR grafted antibody. 
     
     
         3 . The method according to  claim 1 , wherein the antibody is a human antibody. 
     
     
         4 . The method according to  claim 1 , wherein the antibody has a dissociation equilibrium constant (Kd) of less than about 400×10 −12  M. 
     
     
         5 . The method according to  claim 1 , wherein the antibody has an IC 50  for the inhibition of IL-6 production of about 1 nM or less. 
     
     
         6 . The method according to  claim 1 , wherein the antibody has an IC 50  for the inhibition of PGE2 production of about 1 nM or less.